URGN - UroGen Pharma Ltd.

UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

As of Nov 13, 2026: spot at $26.06, ATM IV 93.4%, max pain $25.00, GEX (assumed dealer book) $279.5K of delta per 1% move.

Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (1 expiration, through Nov 20, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$1.28B
Beta
1.64
52-Week Range
16.5-50.81
CEO
Elizabeth Barrett
Employees
300
IPO Date
May 4, 2017
Exchange
NASDAQ

What URGN Looks Like to Options Traders Today

IV rank of 25.3% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); the assumed dealer book's GEX is positive ($279.5K of delta per 1% move): its hedging leans against the trend, damping realized volatility where real dealers are positioned like the book; the 25-delta skew (-0.050) prices puts richer than calls, the typical equity downside-protection skew.

What This Page Covers

The URGN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked URGN overview questions

What is URGN?
URGN is the ticker symbol for UroGen Pharma Ltd., a listed security. UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. Listed on NASDAQ. URGN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What does the URGN options snapshot look like today?
As of Nov 13, 2026, the URGN options snapshot shows spot at $26.06, ATM IV 93.4%, IV rank 25.3%, max pain $25.00, GEX (assumed dealer book) $279.5K of delta per 1% move, expected move 26.78%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
What are URGN's key statistics?
UroGen Pharma Ltd. (URGN) carries a market capitalization of $1.28B, beta of 1.64 relative to the broader market, 52-week range of 16.5-50.81. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does URGN belong to?
UroGen Pharma Ltd. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare URGN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the URGN data on this page?
The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).